ReviewCurrent opinion in infectious diseases2010
Advances in Chagas disease drug development: 2009-2010.
Review in Current opinion in infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.The Cochrane database of systematic reviews · 2016 · on this mapPooled it
- Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.The Journal of antimicrobial chemotherapy · 2013Trial
- Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease.Pathogens (Basel, Switzerland) · 2023Article
- Fexinidazole interferes with the growth and structural organization of Trypanosoma cruzi.Scientific reports · 2022Article
- Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains.Frontiers in pharmacology · 2019Article
- Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends.Current topics in medicinal chemistry · 2018Review
- Lack of Efficacy of Liposomal Amphotericin B Against Acute and ChronicThe American journal of tropical medicine and hygiene · 2017Article
- Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease.PLoS pathogens · 2015Article
- Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.PLoS neglected tropical diseases · 2015Article
- Translational challenges of animal models in Chagas disease drug development: a review.Drug design, development and therapy · 2015Review
- Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method.PloS one · 2015Article
- Article
- Natural products as a source for treating neglected parasitic diseases.International journal of molecular sciences · 2013Article
- Host metabolism regulates intracellular growth of Trypanosoma cruzi.Cell host & microbe · 2013Article
- Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease.Organic letters · 2012Article
- Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice.International journal for parasitology. Drugs and drug resistance · 2012Article
- Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi.Antimicrobial agents and chemotherapy · 2012Article
- Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.Expert review of vaccines · 2012Review
- Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.Antimicrobial agents and chemotherapy · 2012Article
- Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.Current infectious disease reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThe need for better drugs to treat patients with Chagas disease remains urgent. This review summarizes the advancements in drug development over the past 2 years. RECENT
findingsDrug development efforts are almost exclusively occurring as preclinical research, although phase II studies for the antifungal drug, posaconazole, and a prodrug of ravuconazole are being planned. Several recent laboratory investigations demonstrate anti-Trypanosoma cruzi activity of novel small molecules in animal models. These include nonpeptidic cruzain inhibitors, novel inhibitors of the sterol 14α-demethylase enzyme, new compounds (arylimidamides) related to pentamidine, derivatives of nifurtimox, compounds using ruthenium complexes, and several natural products. The recent implementation of a high-throughput screen of more than 300 000 compounds against intracellular T. cruzi amastigotes done at the Broad Institute is an important development, yielding approximately 300 selective inhibitors, many of which may serve as leads for medicinal chemistry efforts. SUMMARY: Progress is slow, but recent advancements in both drug development and advocacy for research on neglected diseases are encouraging. Efforts to define a target product profile and to harmonize methodologies for testing drugs for Chagas disease are described herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.